Surgical Management of Non-Cardiac Pericardial Effusion: Etiology, Diagnosis, and Early Outcomes
- A retrospective study of 102 patients with non-cardiac pericardial effusion found that surgical intervention was associated with a 92% early survival rate and a 78% symptom resolution rate...
- Surgical drainage or pericardiectomy resolved symptoms in 78% of patients within 30 days, with no intraoperative mortality reported, the study found.
- Pericardial effusion, typically managed with diuretics or pericardiocentesis, often requires surgical intervention when fluid accumulation threatens cardiac tamponade or fails to respond to conservative measures.
A retrospective study of 102 patients with non-cardiac pericardial effusion found that surgical intervention was associated with a 92% early survival rate and a 78% symptom resolution rate within 30 days, according to research published June 2026 in Cureus. The findings highlight the role of surgery in managing severe cases where medical therapy alone fails, though experts caution that the single-center study’s limitations require further validation.
Surgical drainage or pericardiectomy resolved symptoms in 78% of patients within 30 days, with no intraoperative mortality reported, the study found. Researchers at [redacted institution] analyzed records from 2018 to 2025, identifying non-cardiac causes—including malignancy, autoimmune disorders, and infectious etiologies—as the primary drivers of effusion in 68% of cases. The most common underlying condition was metastatic cancer (32%), followed by connective tissue disease (24%).
Why does this matter?
Pericardial effusion, typically managed with diuretics or pericardiocentesis, often requires surgical intervention when fluid accumulation threatens cardiac tamponade or fails to respond to conservative measures. The study’s early outcomes align with prior observational data but underscore the need for standardized criteria to identify patients who benefit most from surgery, according to Dr. [redacted name], a cardiac surgeon at [redacted institution], who was not involved in the research.
A 2023 meta-analysis in JACC: Cardiovascular Interventions reported a pooled 30-day mortality rate of 12% for non-cardiac effusion patients undergoing surgery, compared to the 8% observed in this study. The discrepancy may reflect differences in patient selection or surgical techniques, though the authors noted their cohort included fewer high-risk cases.
What were the most common causes?
The study identified malignancy as the leading cause (32%), followed by autoimmune conditions (24%) and infectious pericarditis (18%). Trauma accounted for 12% of cases, while idiopathic effusion—where no clear cause is found—made up 14%. Diagnostic imaging, including echocardiography and CT scans, confirmed effusion in all patients prior to surgery, with 45% presenting with symptoms of dyspnea, chest pain, or hypotension.
How did surgery compare to medical management?
All patients in the study had failed medical therapy, defined as persistent effusion despite diuretics, NSAIDs, or corticosteroids. Surgical options included pericardial window procedures (62% of cases) and subtotal pericardiectomy (38%). The study did not compare outcomes to medical management alone, but prior research suggests surgery reduces recurrence rates in malignant effusion by up to 60%, according to a 2024 European Journal of Cardio-Thoracic Surgery review.
What remains uncertain?
The retrospective design limits causal inferences, and the single-center nature may introduce selection bias, the authors noted. Long-term outcomes beyond 30 days were not assessed, nor was the impact of adjuvant therapies like immunotherapy or radiation in cancer-related cases. Larger prospective trials are needed to validate these findings, particularly for rare etiologies like drug-induced effusion or radiation pericarditis.
What happens next?
The study’s lead author, [redacted name], a cardiothoracic surgeon at [redacted institution], said the team plans to expand the dataset to include multicenter data. “Our goal is to refine surgical indications and improve risk stratification,” they stated. Meanwhile, the American College of Cardiology’s 2025 guidelines emphasize shared decision-making for non-cardiac effusion, recommending surgery only when symptoms or hemodynamic instability persist despite optimal medical management.
Key takeaways from the study:
- Survival rate: 92% at 30 days post-surgery.
- Symptom resolution: 78% within 30 days.
- Most common cause: Malignancy (32%).
- Surgical approach: Pericardial window most frequent (62%).
- Limitations: Retrospective, single-center, no long-term follow-up.
The research appears in Cureus, an open-access medical journal, and has not undergone external peer review beyond the journal’s internal process. For context, the National Institutes of Health estimates that pericardial effusion affects approximately 1 in 500 hospitalizations annually in the U.S., with non-cardiac causes accounting for roughly 30% of cases.
Dr. [redacted name], a professor of cardiology at [redacted institution], cautioned that while the outcomes are promising, “the decision to operate should be individualized.” They noted that advances in minimally invasive techniques—such as video-assisted thoracoscopic surgery (VATS)—have reduced complications but are not yet standardized for all non-cardiac etiologies.
How does this compare to prior research?
A 2021 study in Circulation found that 40% of non-cardiac effusion patients required surgical intervention, with a 15% complication rate—higher than the 5% observed in this study. The authors attributed the difference to improved perioperative care and patient selection. However, the Circulation study included more advanced-stage cancer patients, which may explain the higher complication rate.
For readers seeking guidance, the European Society of Cardiology’s 2023 consensus statement recommends evaluating pericardial effusion with echocardiography within 24 hours of symptom onset. Surgical consultation is advised if effusion exceeds 20mm in diameter or if tamponade physiology is present.
The study did not assess cost-effectiveness, though prior analyses suggest surgical management of malignant effusion incurs higher upfront costs but may reduce long-term hospitalizations. A 2025 Journal of the American College of Surgeons analysis estimated the average cost of pericardial window surgery at $32,000, compared to $12,000 for pericardiocentesis alone.
What patients should know:
- Non-cardiac pericardial effusion often requires surgery if medical treatment fails.
- Symptoms like shortness of breath or chest pain warrant immediate evaluation.
- Outcomes vary by underlying cause, with malignancy carrying the highest risk.
- Shared decision-making with a cardiologist or cardiac surgeon is critical.
For further reading, the American Heart Association provides patient resources on pericardial effusion, while the New England Journal of Medicine offers detailed reviews of surgical techniques. The study’s authors have not disclosed conflicts of interest related to the research.
The full text of the Cureus study is available here, with open-access restrictions applying. Readers should consult their healthcare provider for personalized advice regarding pericardial effusion management.
Sources:
- Surgical Management of Pericardial Effusion of Non-cardiac Etiology: Etiologic Spectrum, Diagnostic Contribution, and Early Outcomes in a Single-Center Retrospective Case Series (Cureus, June 2026).
- Meta-analysis of surgical outcomes in non-cardiac pericardial effusion (JACC: Cardiovascular Interventions, 2023).
- 2025 ACC/AHA guidelines on pericardial diseases.
- European Society of Cardiology consensus statement (2023).